Heart drug may prevent 'No-Reflow' after stenting
NCT ID NCT07536802
First seen Apr 30, 2026 · Last updated May 08, 2026 · Updated 3 times
Summary
This study tests whether giving the drug adenosine before emergency angioplasty (stenting) can prevent the 'no-reflow' problem, where blood still doesn't flow well after the artery is opened. About 1,148 adults having a heart attack (STEMI) will be randomly assigned to receive adenosine or a placebo before the procedure. The goal is to see if adenosine reduces the chance of slow or blocked blood flow after stenting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institute of Cardiovascular Diseases
RECRUITINGKarachi, Sindh, 75510, Pakistan
-
National Institute of Cardiovascular Diseases
RECRUITINGKarachi, Sindh, 75510, Pakistan
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.